The chief executive officer of Baby Bunting, Mark Teperson, has been diagnosed with myelofibrosis, a rare form of bone marrow cancer.
The Australian baby goods retailer confirmed the news in an ASX update today, pointing out that Teperson received a DIPSS-0 low-risk prognosis, which is the most favourable category and is associated with slow disease progression, a long-term outlook and broad treatment options.
Teperson confirmed that his condition and the associated non-invasive treatment plan will not impact his ability to perform his duties as CEO, and advised the board of his firm commitment to continuing in the role.
“The board fully supports Mark and his continued leadership of Baby Bunting,” company chair Stephen Roche said. “We appreciate his decision to release details of his condition, and we remain confident in his ability to execute our strategy in the years ahead.”
Teperson said he is extremely grateful to the board, the leadership team and to his family “for their incredible support during what has been a challenging few weeks.”
“Thankfully, the low-risk prognosis means my ability to lead the business is not affected, and my commitment to Baby Bunting and our strategy remains unwavering,” Teperson said.
“Nevertheless, I have made the decision to announce this matter, as I believe full transparency is essential to uphold the trust and confidence we have built with our stakeholders and the market.”
Baby Bunting sells baby products across various categories, including babywear, footwear and accessories alongside hard goods such as prams and cots.